Loren Phillip Brook , MD

Residency : Ohio State University Wexner Medical Center Columbus, OH, 2016 (Internal Medicine)

MD: University of Cincinnati College of Medicine Cincinnati, OH, 2013

BS: Ohio State University Columbus, OH, 2008 (Biology)

MS: University of Cincinnati College of Allied Health Sciences Cincinnati, OH, 2012 (Nutrition)

Fellowship: University of Cincinnati Medical Center Cincinnati, OH, 2019 (Gastroenterology and Hepatology)

American Board of Internal Medicine (Gastroenterology) (Certification Date: 11-20-2019 )

American Board of Internal Medicine (Certification Date: 08-25-2016 )

Gastroenterology

Fatty Liver

Inflammatory Bowel Disease (IBD)

Digestive Diseases

Internal Medicine

Grant: #SPARC IBD Site Agreement Investigators:Brook, Loren; Reynolds, Gorman; Yacyshyn, Bruce 07-13-2018 -07-12-2021 Crohn's & Colitis Foundation of American Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD) Role:PI $256,060.34 Active Level:Private Non-Profit

Grant: #M20-371 Investigators:Brook, Loren 05-01-2022 -04-30-2025 AbbVie, Inc. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease (CD): AIM-CD Role:PI 456642.40 Hold Level:Industry

Grant: #IM047029 Investigators:Brook, Loren 08-04-2023 -12-10-2026 Celgene Corporation A Phase 4, Global, Prospective, Open label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Biomarker Response in Participants with Moderate to Severe Ulcerative Colitis in Clin Role:PI 108053.92 Hold Level:Industry

Grant: #ROAR 000422 Investigators:Brook, Loren 10-03-2023 -10-03-2026 Ferring Pharmaceuticals REBYOTA for the Prevention of Recurrence of Clostridioides Difficile Infection (CDI) in Adult Patients: An Observational Study Role:PI 22714.99 Active Level:Industry

Grant: #GO44296 Investigators:Brook, Loren 10-13-2023 -10-13-2026 F. Hoffmann-La Roche Ltd Roche Cancer Screening Collection Study Role:PI 269221.01 Hold Level:Industry

Grant: #DUET Ulcerative Colitis 78934804UC2001 Investigators:Brook, Loren 04-10-2024 -05-09-2024 Janssen Research & Development, LLC A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group,Multicenter Study to Evaluate the Efficacy and Safety of Induction and MaintenanceCombination Therapy Role:PI 27525.00 Hold Level:Industry

Grant: #DUET Crohns 78934804CRD2001 Investigators:Brook, Loren 04-10-2024 -05-09-2024 Parexel International, LLC A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group,Multicenter Study to Evaluate the Efficacy and Safety of Induction and MaintenanceCombination Therapy Role:PI 26175.00 Hold Level:Industry

Grant: #M25-540 Investigators:Brook, Loren 03-17-2025 -03-17-2028 AbbVie, Inc. A Phase 3b, Multicenter, Randomized, Open-Label Study of Risankizumab Compared to Vedolizumab for the Treatment of Adult Subjects With Moderate to Severe Ulcerative Colitis Who Naive to Targeted Thera Role:PI 6.75 Hold Level:Industry

Peer Reviewed Publications

Thomas, Kelly; Schrager, Jason; Neel, Robert; Brook, Loren Percutaneous endoscopic gastrostomy tube placement in amyotrophic lateral sclerosis: a case series with a multidisciplinary, team-based approach.Annals of gastroenterology, , 33 (5 ) ,480-484 More Information

Academic - Medical Science Building
231 Albert Sabin Way ML 0595
Cincinnati  Ohio, 45267
Phone: 513-558-7200
Fax: 513-558-6013
brookln@uc.edu